Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era...
Disability
2025 Therap National Conference Day Two: Key Session by Justin Brockie on Therap in the Age of Artificial Intelligence
TORRINGTON, Conn., Jan. 29, 2025 /PRNewswire/ -- Therap Services, the premier provider of HIPAA-compliant electronic documentation solutions for organizations and...
JOSHIN AND INTEGRATE AUTISM EMPLOYMENT ADVISORS ANNOUNCE PARTNERSHIP TO BRING HOLISTIC NEURODIVERSITY SUPPORT SERVICES TO EMPLOYERS
MINNEAPOLIS, Jan. 29, 2025 /PRNewswire/ -- Joshin, a leading provider of neurodivergent and disability support services, and Integrate Autism Employment...
Brain Aneurysm Foundation’s Executive Director Christine Buckley to Speak at the 2025 International Stroke Conference
HANOVER, Mass., Jan. 29, 2025 /PRNewswire/ -- The Brain Aneurysm Foundation (BAF), the leading advocacy organization supporting education, research, and policy to...
Ambulatory Care Nurses Week: A Nationwide Tribute to Nursing Excellence
PITMAN, N.J., Jan. 28, 2025 /PRNewswire/ -- The American Academy of Ambulatory Care Nursing (AAACN) invites nurses, health care organizations, and communities...
Sera Prognostics to Host Virtual R&D Day on January 31
Event will showcase results of Company's pivotal PRIME study and include the principal investigator SALT LAKE CITY, Jan. 27, 2025...
CTA FOUNDATION CELEBRATES AN INCREDIBLE CES 2025, HIGHLIGHTING ACCESSIBILITY INNOVATION AND COLLABORATION
LAS VEGAS, Jan. 21, 2025 /PRNewswire/ -- The Consumer Technology Association (CTA)® Foundation wrapped up an exciting and impactful week at...
Helius Medical Technologies, Inc. Announces Strong Enrollment of its Stroke Pivotal Study Exceeding Initial Target
--128 enrolled participants, as of December 31, 2024, exceeds initial target of 90 participants-- --150 maximum participant enrollment projected by...
JOSHIN AND AON COLLABORATE TO OFFER SPECIALIZED NEURODIVERSITY SUPPORT SERVICES TO EMPLOYERS
Collaboration delivers strategic Neurodiversity initiatives, with comprehensive support and advanced analytics and insights tailored to both individual and organizational needs....
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum
Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription...
Lifeward Announces $5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a...
Veterans Benefits Administration awards medical disability examination services contract to Leidos QTC Health Services
RESTON, Va., Jan. 6, 2025 /PRNewswire/ -- Leidos (NYSE:LDOS) today announced that its wholly owned subsidiary, QTC Medical Services, operating under the...
Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business
MIAMI, FL, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Lifeward Announces Postponement of its Extraordinary General Meeting of Shareholders
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”),...
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx's VYVGART® and VYVDURA portfolio...
Braille Institute Library to Host Livestream Event with Pulitzer Prize Finalist Andrew Leland on January 16, 2025
Leland to discuss his best-selling book, “The Country of the Blind: A Memoir at the End of Sight” LOS ANGELES,...
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the...
inQUEST CEO Appointed to Access Living Board
Hoesman, Access Living to Advance Inclusion for 'Nation's Largest Minority Group' CHICAGO, Dec. 17, 2024 /PRNewswire/ -- Scott Hoesman, CEO and...
Large Clinical Study Finds Home-based Virtual Reality Device Creates Greater Relief for High Impact Chronic Pain Patients
Secondary analysis of a randomized, placebo-controlled study of 1,000+ participants indicated that FDA-authorized RelieVRx® yielded clinically meaningful pain intensity and pain...
New ALS Association-Led Research Finds Specialists Diagnose ALS Twice as Fast as General Neurologists
Groundbreaking thinkALS™ Tool Empowers Providers to Identify and Refer Patients Quicker ARLINGTON, Va., Dec. 10, 2024 /PRNewswire/ -- It can take...